dc.contributor.author
Alonso-Molero, Jéssica
dc.contributor.author
Molina de la Torre, Antonio José
dc.contributor.author
Jiménez Moleón, José Juan
dc.contributor.author
Pérez Gómez, Beatriz
dc.contributor.author
Martín Sánchez, Vicente
dc.contributor.author
Moreno Aguado, Víctor
dc.contributor.author
Amiano, Pilar
dc.contributor.author
Ardanaz, Eva
dc.contributor.author
Sanjosé Llongueras, Silvia de
dc.contributor.author
Salcedo, Immaculada
dc.contributor.author
Fernández Tardón, Guillermo
dc.contributor.author
Alguacil, Juan
dc.contributor.author
Salas, Dolores
dc.contributor.author
Marcos Gragera, Rafael
dc.contributor.author
Chirlaque, María Dolores
dc.contributor.author
Aragonès Sanz, Núria
dc.contributor.author
Castaño-Vinyals, Gemma
dc.contributor.author
Pollán, Marina
dc.contributor.author
Kogevinas, Manolis
dc.contributor.author
Llorca Díaz, Javier
dc.date.issued
2022-03-30T08:38:17Z
dc.date.issued
2022-03-30T08:38:17Z
dc.date.issued
2019-11-21
dc.date.issued
2022-03-28T14:55:26Z
dc.identifier
https://hdl.handle.net/2445/184470
dc.description.abstract
PURPOSE: Since 2016, the multicase-control study in Spain (MCC-Spain) has focused towards the identification of factors associated with cancer prognosis. Inception cohorts of patients with colorectal, breast and prostate cancers were assembled using the incident cases originally recruited. PARTICIPANTS: 2140 new cases of colorectal cancer, 1732 of breast cancer and 1112 of prostate cancer were initially recruited in 12 Spanish provinces; all cancers were incident and pathologically confirmed. Follow-up was obtained for 2097 (98%), 1685 (97%) and 1055 (94.9%) patients, respectively. FINDINGS TO DATE: Information gathered at recruitment included sociodemographic factors, medical history, lifestyle and environmental exposures. Biological samples were obtained, and 80% of patients were genotyped using a commercial exome array. The follow-up was performed by (1) reviewing medical records; (2) interviewing the patients by phone on quality of life; and (3) verifying vital status and cause of death in the Spanish National Death Index. Ninety-seven per cent of recruited patients were successfully followed up in 2017 or 2018; patient-years of follow-up were 30 914. Most colorectal cancers (52%) were at clinical stage II or lower at recruitment; 819 patients died in the follow-up and the 5-year survival was better for women (74.4%) than men (70.0%). 71% of breast cancers were diagnosed at stages I or II; 206 women with breast cancer died in the follow-up and the 5-year survival was 90.7%. 49% of prostate cancers were diagnosed at stage II and 32% at stage III; 119 patients with prostate cancer died in the follow-up and the 5-year survival was 93.7%. FUTURE PLANS: MCC-Spain has built three prospective cohorts on highly frequent cancers across Spain, allowing to investigate socioeconomic, clinical, lifestyle, environmental and genetic variables as putative prognosis factors determining survival of patients of the three cancers and the inter-relationship of these factors.
dc.format
application/pdf
dc.publisher
BMJ Publishing Group
dc.relation
Reproducció del document publicat a: https://doi.org/10.1136/bmjopen-2019-031904
dc.relation
BMJ Open, 2019, vol. 9, num. 11, p. e031904-e031904
dc.relation
https://doi.org/10.1136/bmjopen-2019-031904
dc.rights
cc-by (c) Alonso-Molero, Jéssica et al., 2019
dc.rights
https://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Ciències Clíniques)
dc.subject
Càncer de mama
dc.subject
Càncer colorectal
dc.subject
Càncer de pròstata
dc.subject
Colorectal cancer
dc.subject
Prostate cancer
dc.title
Cohort profile: the MCC-Spain follow-up on colorectal, breast and prostate cancers: study design and initial results
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion